{"id":{"repo_id":"sdstate","oai_identifier":"oai:openprairie.sdstate.edu:etd-2908"},"canonical_url":"https://search.ndltd.org/etd/sdstate/oai:openprairie.sdstate.edu:etd-2908","repository":{"repo_id":"sdstate","name":"South Dakota State University","base_url":"https://openprairie.sdstate.edu/do/oai/"},"display":{"title":"A Nano-particle Based Adjuvant to Treat Breast Cancer Induced Secondary Lymphedema","abstract":"Breast cancer is among the most commonly diagnosed cancers in women in the United States. Traditional treatment for breast cancer, sentinel lymph node excision, leads many women to develop secondary lymphedema. Currently, there are no curative treatments for secondary lymphedema, leaving these women with recurrent infections, limited arm function, and an overall decrease in quality of life. There is promising data in the use of surgical and pharmacological interventions to regenerate damaged lymphatic vessels through delivery of lymphangiogenic growth factors and autologous lymphatic vessel transplantation. In this study, we determined that a Zein and gelatin formulation encapsulating ANG-2 and VEGF-C, in combination with autotransplantation of the lymph node, is a desirable delivery system for the treatment of breast cancer induced secondary lymphedema. Through a series of in vitro studies, we demonstrated the sustained release of lymphangiogenic growth factors, ANG-2 and VEGF-C, from this formulation up to 14 days post treatment. Treatment of this formulation on lymphatic endothelial cells indicated it is biocompatible. In vivo testing on a sheep model of lymphedema demonstrated that the formulation of Zein and gelatin encapsulating ANG-2 and VEGF-C stimulated the reestablishment of lymphatics as early as 6 weeks following lymph node excision. In the future, utilizing this technique of lymph node","abstract_html":"Breast cancer is among the most commonly diagnosed cancers in women in the United States. Traditional treatment for breast cancer, sentinel lymph node excision, leads many women to develop secondary lymphedema. Currently, there are no curative treatments for secondary lymphedema, leaving these women with recurrent infections, limited arm function, and an overall decrease in quality of life. There is promising data in the use of surgical and pharmacological interventions to regenerate damaged lymphatic vessels through delivery of lymphangiogenic growth factors and autologous lymphatic vessel transplantation. In this study, we determined that a Zein and gelatin formulation encapsulating ANG-2 and VEGF-C, in combination with autotransplantation of the lymph node, is a desirable delivery system for the treatment of breast cancer induced secondary lymphedema. Through a series of in vitro studies, we demonstrated the sustained release of lymphangiogenic growth factors, ANG-2 and VEGF-C, from this formulation up to 14 days post treatment. Treatment of this formulation on lymphatic endothelial cells indicated it is biocompatible. In vivo testing on a sheep model of lymphedema demonstrated that the formulation of Zein and gelatin encapsulating ANG-2 and VEGF-C stimulated the reestablishment of lymphatics as early as 6 weeks following lymph node excision. In the future, utilizing this technique of lymph node","abstract_has_math":false,"creators":["Thicke, Brianne"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Thesis - University Access Only","degree_discipline":"Veterinary and Biomedical Sciences","degree_department":null,"school":null,"contributors":["Alan Young"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:58:14Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":["http://rightsstatements.org/vocab/InC/1.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://openprairie.sdstate.edu/etd/1889","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://openprairie.sdstate.edu/etd/1889","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://openprairie.sdstate.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Aopenprairie.sdstate.edu%3Aetd-2908","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Alan Young"]},{"key":"dc:creator","label":"Author","values":["Thicke, Brianne"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2017-09-28T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2015-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Veterinary and Biomedical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis - University Access Only"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["http://rightsstatements.org/vocab/InC/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://openprairie.sdstate.edu/etd/1889"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Breast cancer is among the most commonly diagnosed cancers in women in the United States. Traditional treatment for breast cancer, sentinel lymph node excision, leads many women to develop secondary lymphedema. Currently, there are no curative treatments for secondary lymphedema, leaving these women with recurrent infections, limited arm function, and an overall decrease in quality of life. There is promising data in the use of surgical and pharmacological interventions to regenerate damaged lymphatic vessels through delivery of lymphangiogenic growth factors and autologous lymphatic vessel transplantation. In this study, we determined that a Zein and gelatin formulation encapsulating ANG-2 and VEGF-C, in combination with autotransplantation of the lymph node, is a desirable delivery system for the treatment of breast cancer induced secondary lymphedema. Through a series of in vitro studies, we demonstrated the sustained release of lymphangiogenic growth factors, ANG-2 and VEGF-C, from this formulation up to 14 days post treatment. Treatment of this formulation on lymphatic endothelial cells indicated it is biocompatible. In vivo testing on a sheep model of lymphedema demonstrated that the formulation of Zein and gelatin encapsulating ANG-2 and VEGF-C stimulated the reestablishment of lymphatics as early as 6 weeks following lymph node excision. In the future, utilizing this technique of lymph node"]},{"key":"dc:title","label":"Title","values":["A Nano-particle Based Adjuvant to Treat Breast Cancer Induced Secondary Lymphedema"]}]}],"canonical_facts":{"dc:contributor":["Alan Young"],"dc:creator":["Thicke, Brianne"],"dc:date.available":["2017-09-28T07:00:00Z"],"dc:date.created":["2015-01-01T08:00:00Z"],"dc:description.abstract":["Breast cancer is among the most commonly diagnosed cancers in women in the United States. Traditional treatment for breast cancer, sentinel lymph node excision, leads many women to develop secondary lymphedema. Currently, there are no curative treatments for secondary lymphedema, leaving these women with recurrent infections, limited arm function, and an overall decrease in quality of life. There is promising data in the use of surgical and pharmacological interventions to regenerate damaged lymphatic vessels through delivery of lymphangiogenic growth factors and autologous lymphatic vessel transplantation. In this study, we determined that a Zein and gelatin formulation encapsulating ANG-2 and VEGF-C, in combination with autotransplantation of the lymph node, is a desirable delivery system for the treatment of breast cancer induced secondary lymphedema. Through a series of in vitro studies, we demonstrated the sustained release of lymphangiogenic growth factors, ANG-2 and VEGF-C, from this formulation up to 14 days post treatment. Treatment of this formulation on lymphatic endothelial cells indicated it is biocompatible. In vivo testing on a sheep model of lymphedema demonstrated that the formulation of Zein and gelatin encapsulating ANG-2 and VEGF-C stimulated the reestablishment of lymphatics as early as 6 weeks following lymph node excision. In the future, utilizing this technique of lymph node"],"dc:identifier":["https://openprairie.sdstate.edu/etd/1889"],"dc:language":["en"],"dc:rights":["http://rightsstatements.org/vocab/InC/1.0/"],"dc:title":["A Nano-particle Based Adjuvant to Treat Breast Cancer Induced Secondary Lymphedema"],"thesis:degree_discipline":["Veterinary and Biomedical Sciences"],"thesis:degree_level":["Thesis - University Access Only"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-11-19T08:58:14Z"}